Novel heterocyclic compounds of formula I:
A-B-D Formula I
or a pharmaceutically acceptable salt thereof,
wherein:
A is selected from the group consisting of a moiety having general Formula II and a moiety having general Formula III:
B is a moiety selected from the group consisting of:
D is a moiety selected from the group consisting of:
which exhibit a dopamine receptor (preferably a D4 receptor) and/or a serotonine receptor (preferably 5HT
A1
agonistic activity), processes of preparing same, pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with the dopaminergic and/or serotonergic systems (e.g., sexual disorders, dyskinesia, anxiety) are disclosed.
公式I的新异环化合物:A-B-D
或其药学上可接受的盐,其中:
A选自具有一般式II和一般式III的基团组成的群体;
B选自基团组成的群体中选择;
D选自基团组成的群体中选择;
这些化合物表现出
多巴胺受体(优选为
D4受体)和/或5HTA1受体(优选为激动剂)的活性。本文还公开了制备这些化合物的方法、含有这些化合物的制药组合物以及在治疗与
多巴胺能和/或5-羟
色胺能系统相关的医学状况(例如性障碍,运动失调,焦虑症)中使用它们的用途。